Fidelis Capital Partners, LLC Alnylam Pharmaceuticals, Inc. Transaction History
Fidelis Capital Partners, LLC
- $1.28 Trillion
- Q3 2025
A detailed history of Fidelis Capital Partners, LLC transactions in Alnylam Pharmaceuticals, Inc. stock. As of the latest transaction made, Fidelis Capital Partners, LLC holds 539 shares of ALNY stock, worth $242,097. This represents 0.02% of its overall portfolio holdings.
Number of Shares
539
Previous 536
0.56%
Holding current value
$242,097
Previous $229 Million
7.1%
% of portfolio
0.02%
Previous 0.02%
Shares
2 transactions
Others Institutions Holding ALNY
# of Institutions
927Shares Held
118MCall Options Held
1.26MPut Options Held
1.49M-
Capital World Investors Los Angeles, CA16.4MShares$7.38 Billion1.07% of portfolio
-
Vanguard Group Inc Valley Forge, PA13.6MShares$6.09 Billion0.09% of portfolio
-
Black Rock Inc. New York, NY9.55MShares$4.29 Billion0.05% of portfolio
-
Capital Research Global Investors Los Angeles, CA7.22MShares$3.24 Billion0.65% of portfolio
-
Jpmorgan Chase & CO New York, NY4.54MShares$2.04 Billion0.14% of portfolio
About ALNYLAM PHARMACEUTICALS, INC.
- Ticker ALNY
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 123,028,000
- Market Cap $55.3B
- Description
- Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. The company's pipeline of investigational RNAi therapeutics focuses on genetic medicines, cardio-metabolic diseases, hepatic infectious diseases, and central nervous system...